Alimentary Pharmacology & Therapeutics
Wiley Online Library : Alimentary Pharmacology & Therapeutics
23 followers
[0] 13 篇文章/周
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
Our cohort of patients in the IMBrave150 group had a median OS of 26.5 months and a median PFS of 7.4 months, which were longer than in the phase 3 trial. ・Patients who did not meet the criteria for the phase 3 trial, particularly those with mALBI grade 1 or 2a, had an equally good prognosis. Summary Background Atezolizumab plus bevacizumab...
Thu May 9, 2024 11:18
Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
Alimentary Pharmacology &Therapeutics, EarlyView.
Wed May 8, 2024 11:02
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
Alimentary Pharmacology &Therapeutics, EarlyView.
Wed May 8, 2024 11:02
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
Alimentary Pharmacology &Therapeutics, EarlyView.
Wed May 8, 2024 11:02
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply
Alimentary Pharmacology &Therapeutics, Volume 59, Issue 11, Page 1465-1466, June 2024.
Tue May 7, 2024 11:48
Editorial: Hepatitis C virus eradication improves skeletal muscle mass
Alimentary Pharmacology &Therapeutics, Volume 59, Issue 11, Page 1446-1447, June 2024.
Tue May 7, 2024 11:48